Tags

Type your tag names separated by a space and hit enter

Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease.
Kidney Int. 2013 May; 83(5):835-44.KI

Abstract

The leading cause of death in patients with chronic kidney disease (CKD) is cardiovascular disease, with vascular calcification being a key modifier of disease progression. A local regulator of vascular calcification is vitamin K. This γ-glutamyl carboxylase substrate is an essential cofactor in the activation of several extracellular matrix proteins that inhibit calcification. Warfarin, a common therapy in dialysis patients, inhibits the recycling of vitamin K and thereby decreases the inhibitory activity of these proteins. In this study, we sought to determine whether modifying vitamin K status, either by increasing dietary vitamin K intake or by antagonism with therapeutic doses of warfarin, could alter the development of vascular calcification in male Sprague-Dawley rats with adenine-induced CKD. Treatment of CKD rats with warfarin markedly increased pulse pressure and pulse wave velocity, as well as significantly increased calcium concentrations in the thoracic aorta (3-fold), abdominal aorta (8-fold), renal artery (4-fold), and carotid artery (20-fold). In contrast, treatment with high dietary vitamin K1 increased vitamin K tissue concentrations (10-300-fold) and blunted the development of vascular calcification. Thus, vitamin K has an important role in modifying mechanisms linked to the susceptibility of arteries to calcify in an experimental model of CKD.

Links

Publisher Full Text (DOI)

Authors+Show Affiliations

McCabe KM
Department of Biomedical and Molecular Sciences, Queen's University, Kingston, Ontario, Canada.
Booth SL
No affiliation info available
Fu X
No affiliation info available
Shobeiri N
No affiliation info available
Pang JJ
No affiliation info available
Adams MA
No affiliation info available
Holden RM
No affiliation info available

MeSH

AdenineAnimalsAnticoagulantsArteriesBiomarkersBlood PressureDietary SupplementsDisease Models, AnimalDisease ProgressionMaleOsteocalcinPulse Wave AnalysisRatsRats, Sprague-DawleyRenal Insufficiency, ChronicTime FactorsVascular CalcificationVitamin K 1Vitamin K 2Warfarin

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23344475

Citation

McCabe, Kristin M., et al. "Dietary Vitamin K and Therapeutic Warfarin Alter the Susceptibility to Vascular Calcification in Experimental Chronic Kidney Disease." Kidney International, vol. 83, no. 5, 2013, pp. 835-44.
McCabe KM, Booth SL, Fu X, et al. Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. Kidney Int. 2013;83(5):835-44.
McCabe, K. M., Booth, S. L., Fu, X., Shobeiri, N., Pang, J. J., Adams, M. A., & Holden, R. M. (2013). Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. Kidney International, 83(5), 835-44. https://doi.org/10.1038/ki.2012.477
McCabe KM, et al. Dietary Vitamin K and Therapeutic Warfarin Alter the Susceptibility to Vascular Calcification in Experimental Chronic Kidney Disease. Kidney Int. 2013;83(5):835-44. PubMed PMID: 23344475.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dietary vitamin K and therapeutic warfarin alter the susceptibility to vascular calcification in experimental chronic kidney disease. AU - McCabe,Kristin M, AU - Booth,Sarah L, AU - Fu,Xueyan, AU - Shobeiri,Navid, AU - Pang,Judith J, AU - Adams,Michael A, AU - Holden,Rachel M, Y1 - 2013/01/23/ PY - 2013/1/25/entrez PY - 2013/1/25/pubmed PY - 2013/11/20/medline SP - 835 EP - 44 JF - Kidney international JO - Kidney Int VL - 83 IS - 5 N2 - The leading cause of death in patients with chronic kidney disease (CKD) is cardiovascular disease, with vascular calcification being a key modifier of disease progression. A local regulator of vascular calcification is vitamin K. This γ-glutamyl carboxylase substrate is an essential cofactor in the activation of several extracellular matrix proteins that inhibit calcification. Warfarin, a common therapy in dialysis patients, inhibits the recycling of vitamin K and thereby decreases the inhibitory activity of these proteins. In this study, we sought to determine whether modifying vitamin K status, either by increasing dietary vitamin K intake or by antagonism with therapeutic doses of warfarin, could alter the development of vascular calcification in male Sprague-Dawley rats with adenine-induced CKD. Treatment of CKD rats with warfarin markedly increased pulse pressure and pulse wave velocity, as well as significantly increased calcium concentrations in the thoracic aorta (3-fold), abdominal aorta (8-fold), renal artery (4-fold), and carotid artery (20-fold). In contrast, treatment with high dietary vitamin K1 increased vitamin K tissue concentrations (10-300-fold) and blunted the development of vascular calcification. Thus, vitamin K has an important role in modifying mechanisms linked to the susceptibility of arteries to calcify in an experimental model of CKD. SN - 1523-1755 UR - https://www.unboundmedicine.com/medline/citation/23344475/Dietary_vitamin_K_and_therapeutic_warfarin_alter_the_susceptibility_to_vascular_calcification_in_experimental_chronic_kidney_disease_ DB - PRIME DP - Unbound Medicine ER -